B
Bartholomew J. Votta
Researcher at GlaxoSmithKline
Publications - 34
Citations - 4435
Bartholomew J. Votta is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Bone resorption & Transient receptor potential channel. The author has an hindex of 18, co-authored 34 publications receiving 3882 citations.
Papers
More filters
Journal ArticleDOI
Catalytic in vivo protein knockdown by small-molecule PROTACs
Daniel P. Bondeson,Alina Mares,Ian Edward David Smith,Ko Eunhwa,Sebastien Andre Campos,Afjal Hussain Miah,Katie E Mulholland,Natasha Routly,Dennis L. Buckley,Jeffrey L. Gustafson,Nico Zinn,Paola Grandi,Satoko Shimamura,Giovanna Bergamini,Maria Faelth-Savitski,Marcus Bantscheff,Carly S. Cox,Deborah A. Gordon,Ryan R. Willard,John J. Flanagan,Linda N. Casillas,Bartholomew J. Votta,Willem den Besten,Kristoffer Famm,Laurens Kruidenier,Paul S. Carter,John D. Harling,Ian Churcher,Craig M. Crews +28 more
TL;DR: Major improvements to the proteolysis targeting chimeras (PROTACs) method are described, a chemical knockdown strategy in which a heterobifunctional molecule recruits a specific protein target to an E3 ubiquitin ligase, resulting in the target's ubiquitination and degradation.
Journal Article
Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function.
Alison M. Badger,J N Bradbeer,Bartholomew J. Votta,John C. Lee,Jerry L. Adams,Don E. Griswold +5 more
TL;DR: A novel profile of activity strongly suggests that cytokine inhibitors could provide significant benefit in the therapy of chronic inflammatory disease.
Journal ArticleDOI
Inhibition of p38 MAP kinase as a therapeutic strategy
John C. Lee,Sanjay Kumar,Don E. Griswold,David C. Underwood,Bartholomew J. Votta,Jerry L. Adams +5 more
TL;DR: X-ray crystallographic studies of the target enzyme complexed with inhibitor reinforce the observations made from site-directed mutagenesis studies, thereby providing a molecular basis for understanding the kinase selectivity of these inhibitors.
Journal ArticleDOI
N-((1S)-1-{[4-((2S)-2-{[(2,4-Dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a Novel and Potent Transient Receptor Potential Vanilloid 4 Channel Agonist Induces Urinary Bladder Contraction and Hyperactivity: Part I
Kevin S. Thorneloe,Anthony Sulpizio,Zuojun Lin,David J. Figueroa,Angela K. Clouse,Gerald P. McCafferty,Tim P. Chendrimada,Erin S. R. Lashinger,Earl Gordon,Louise C Evans,Blake A. Misajet,Douglas J. DeMarini,Josephine H.L. Nation,Linda N. Casillas,Robert W. Marquis,Bartholomew J. Votta,Steven A. Sheardown,Xiaoping Xu,David P. Brooks,Nicholas J. Laping,Timothy D. Westfall +20 more
TL;DR: Overall TRPV4 plays an important role in urinary bladder function that includes an ability to contract the bladder as a result of the expression of TRPv4 in the UBSM, and 4α-PDD demonstrated a weak ability tocontract bladder strips compared with GSK1016790A.
Journal Article
N-((1S)-1-{[4-((2S)-2-{[2,4-Dichlorophenyl)sulfonyl]amino} -3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl-1-benzothiophene-2- carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: Part I (Journal of Pharmacology and Experimental Therapeutics (2008) 326, (432-442))
Kevin S. Thorneloe,Anthony Sulpizio,Zuojun Lin,David J. Figueroa,Angela K. Clouse,Gerald P. McCafferty,Tim P. Chendrimada,Erin S. R. Lashinger,Earl Gordon,Louise C Evans,Blake A. Misajet,Douglas J. DeMarini,Josephine H.L. Nation,Linda N. Casillas,Robert W. Marquis,Bartholomew J. Votta,Steven A. Sheardown,Xiaoping Xu,David P. Brooks,Nicholas J. Laping,Timothy D. Westfall +20 more